Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Blood

Volumn 127, Issue 25, 2016, Pages 3165-3174

  Paiva, Bruno ^a   Cedena, Maria Teresa ^b   Puig, Noemi ^c   Arana, Paula ^a   Vidriales, Maria Belen ^c   Cordon, Lourdes ^d   Flores Montero, Juan ^c   Gutierrez, Norma C ^c   Martín Ramos, María Luisa ^b   Martinez Lopez, Joaquin ^b   Ocio, Enrique M ^c   Hernandez, Miguel T ^e   Teruel, Ana Isabel ^f   Rosiñol, Laura ^g   Echeveste, María Asunción ^h   Martinez, Rafael ⁱ   Gironella, Mercedes ^j   Oriol, Albert ^k   Cabrera, Carmen ^l   Martin, Jesus ^m   Bargay, Joan ⁿ   Encinas, Cristina ^o   Gonzalez, Yolanda ^p   Van Dongen, Jacques J M ^q   Orfao, Alberto ^c   Bladé, Joan ^g   Mateos, Maria Victoria ^c   Lahuerta, Juan José ^b   San Miguel, Jesús F ^a   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universidad Complutense   (Spain)

^c CSIC   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁿ Hospital Sont Llatzer   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^p Dr Josep Trueta University Hospital   (Spain)

^q ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER; THALIDOMIDE; TUMOR MARKER; VINCRISTINE;

AGED; ARTICLE; CANCER PATIENT; CYTOGENETICS; DISEASE CONTROL; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL MONITORING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; DRUG MONITORING; FEMALE; IMMUNITY; MALE; MORTALITY; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BIOMARKERS, TUMOR; DEXAMETHASONE; DRUG MONITORING; FEMALE; HUMANS; IMMUNITY; MALE; MELPHALAN; MONITORING, PHYSIOLOGIC; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; THALIDOMIDE; VINCRISTINE;

EID: 84977534337     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-705319     Document Type: Article

References (33)

1. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
2. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
3. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
4. San Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
5. Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
6. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
7. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043-3051.
8. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.
9. Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459-3466.
10. Landgren O, Gormley N, Turley D, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDA-NCI roundtable symposium. Am J Hematol. 2014;89(12):1159-1160.
11. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059-3068.
12. Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12(5):286-295.
13. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
14. Morgan GJ, Davies FE, Gregory WM, et al; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118(5):1231-1238.
15. Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29(12):1627-1633.
16. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-397.
17. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.
18. Mateos MV, Oriol A, Martínez-López J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124(12):1887-1893.
19. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
20. Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99(9):e162-e164.
21. Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746-754.
22. Mateos MV, Martínez-López J, Hernández MT, et al. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood. 2016;127(4):420-425.
23. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
24. van Dongen JJ, Lhermitte L, Böttcher S, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975.
25. Paiva B, Vídriales MB, Rosiñol L, et al; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and longterm disease control. Leukemia. 2013;27(10):2056-2061.
26. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712-2717.
27. Paiva B, Gutiérrez NC, Rosiñol L, et al; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-691.
28. Paiva B, Vidriales MB, Cerveró J, et al; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
29. Paiva B, Puig N, García-Sanz R, San Miguel JF; Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res. 2015;21(9):2001-2008.
30. Kalina T, Flores-Montero J, van der Velden VH, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
31. Flores-Montero J, Paiva B, Sanoja-Flores L, et al. Next generation flow (NGF) for high sensitive detection of minimal residual disease (MRD) in multiple myeloma (MM) [abstract]. Blood. 2015;126(23). Abstract 367.
32. Martinez-Lopez J, Blade J, Mateos MV, et al; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna. Longterm prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-534.
33. Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79-86.